Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | PI4KA | P42356 | 4/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 4/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 4/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 4/20 | 0.45 |
| ▸ | FBP1 | P09467 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | APEX1 | P27695 | 1/20 | 0.37 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | DNMT3B | Q9UBC3 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6346446 | 0.80 | PI4KA (0.56) | ALDH1A1NPSR1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5357687 | 0.70 | FPR2 (0.35) | ALDH1A1FBP1LMNA | |
| SCHEMBL870861 | 0.65 | PI4KA (0.62) | ALDH1A1NPSR1PI4KAPI4K2BPI4K2A | |
| SCHEMBL5369925 | 0.62 | PI4KA (0.48) | ALDH1A1NPSR1PI4KAPI4K2BPI4K2A | |
| Edetic Acid SCHEMBL7770900 | 0.62 | PI4KA (0.48) | ALDH1A1NPSR1PI4KAPI4K2BPI4K2A | |
| SCHEMBL25308000 | 0.61 | TSHR (0.55) | ALDH1A1 | |
| SCHEMBL11126525 | 0.60 | CETP (0.47) | ALDH1A1 | |
| SCHEMBL14778450 | 0.60 | CSF1R (0.65) | PI4KAPI4K2BPI4K2API4KBLMNA | |
| SCHEMBL27924143 | 0.60 | TSHR (0.50) | ALDH1A1LMNACYP3A4PKM | |
| SCHEMBL1319783 | 0.59 | TSHR (0.64) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285543-B2 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | DANG QUN | 2005-12-15 | — | — | US | disclosed |
| US-6967193-B1 | Purine inhibitors of fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2005-11-22 | — | — | US | disclosed |
| US-6284748-B1 | ANTIDIABETIC AGENT | METABASIS THERAPEUTICS, INC. | 2001-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050277619-A1 | Novel purine inhibitors of fructose-1,6-bisphosphatase | FBP1, PNP, PPA1 | ALDH1A1 429/4885NPSR1 2076/4885PI4KA 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.